Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →
logo
Get CLEATUSFree Trial

Research and Development Manufacture of mAb114 for Ebola

Active
75A50119C00059Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The contract numbered 75A50119C00059 was awarded to Ridgeback Biotherapeutics as a Letter contract for the research and development manufacture of mAb114, a monoclonal antibody treatment for Ebola. This award was made under a justification for other than full and open competition based on FAR 6.302-2, which addresses unusual and compelling urgency. The contract was issued by the Administration for Strategic Preparedness and Response within the Department of Health and Human Services and falls under the NAICS code 541714, which pertains to research and development in the physical, engineering, and life sciences. The contract posting occurred on December 3, 2019, and the work is performed in Miami, Florida. The special notice included a redacted Justification and Approval document required by FAR 6.305(b) to support the non-competitive award decision due to the urgent public health threat posed by Ebola. The specified point of contact for this contract is Ethan Mueller from the Department of Health and Human Services, who can be reached via email. This procurement highlights the government's expedited actions to address a pressing health emergency through targeted research and development partnerships.

General Info

Ridgeback Biotherapeutics awarded urgent, sole-source contract to develop Ebola antibody treatment.

Agency

Department Of Health And Human Services → Administration For Strategic Preparedness And ResponseView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Miami, FL, USA

Set-Aside

NONE

Documents

(1)

Final+Posted+J%26A_Redacted.pdf

PDF

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

Posted

special-notice

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → Administration For Strategic Preparedness And Response
Contacts1 person available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → Administration For Strategic Preparedness And Response
View Agency Profile
Office AddressN/A
Contacts
Ethan Mueller
contact@example.gov

Full Description

Show more
The purpose of this special notice is to in accordance with FAR 6.305 (b) to post a redacted Justification and Approval for Other Than Full and Open Competition. Contract Number 75A50119C00059 was awarded to Ridgeback Biotherapeutics as a Letter contract for the Research and Development Manufacture of mAb114 for Ebola in accordance with FAR Part 6.302-2 Unusual and Compelling Urgency.

Similar Contracts

NAICS: 541714
New
Federal
Purchase of Methylation Custom Probes for sequencingThe National Institutes of Health, under the Department of Health and Human Services, is seeking proposals for the purchase of customized methylation probes designed for sequencing applications. The solicitation, identified by number 75N98026Q00783, was posted on July 14, 2026, with a response deadline of July 21, 2026, at 8:00 PM Eastern Time. This is a combined solicitation with no set-aside designation, meaning it is open to all eligible businesses regardless of size or ownership characteristics. The North American Industry Classification System code for this procurement is 541714, indicating it pertains to research and development in the physical, engineering, and life sciences. The contract will be administered from the agency’s office in Bethesda, Maryland, with performance expected to occur in Durham, North Carolina, at a ZIP code of 27709. All inquiries and submissions should be directed to Francisca K. Wagstaff, the primary point of contact, via email at wagstaff@nih.gov. The full solicitation details and submission portal are accessible through the SAM.gov website using the provided URL.
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 541714
New
Grant
Advancing Outbreak Detection, Notification, and Response Capacity by Implementing 7-1-7 in Partner CountriesThis funding opportunity supports the strengthening of public health systems in partner countries outside the United States and its territories to achieve the 7-1-7 target—detecting biological threats within seven days, notifying relevant authorities within one day, and initiating a coordinated response within seven days. The initiative advances U.S. global health interests by building sustainable, locally led capacities for outbreak detection, notification, and response, with an emphasis on burden sharing, accountability, and efficiency. Activities include enhancing surveillance infrastructure, expanding laboratory networks, improving cross-sector and cross-border data flow, and strengthening emergency response operations to mitigate health and economic impacts. Implementation is targeted in countries where CDC has an established presence, including Bangladesh, Ghana, India, Kenya, and others, with the ultimate goal of fostering long-term self-reliance and stability in recipient nations. The solicitation, issued as a Notice of Funding Opportunity under CDC-RFA-JG-26-0214, is open for applications through Grants.gov with a deadline of August 14, 2026, and anticipated award start date of September 30, 2026, for a five-year performance period. Applications must be submitted as a cohesive package under a 90-page limit for all appendices and supporting materials, with a cap of 60 pages for the project narrative and one page for the summary. Applicants must demonstrate organizational capacity, past experience, and a robust evaluation and performance measurement plan, with evaluation weighted toward background and approach (35 points) and organizational capacity (35 points), followed by evaluation and performance measurement (30 points). Awards are made through a merit-based trade-off process, not LPTA, and may be influenced by geographic diversity and public health priorities. Recipients must adhere to 2 CFR 200 regulations, submit required financial and performance reports, and comply with CDC’s priorities including transparency and evidence-based practice. Special requirements include providing a detailed organizational chart, resumes for key personnel, an indirect cost agreement if claiming overhead, and a letter to qualify for local partner funding preference, which may yield a 10-point bonus. All applicants must hold an active Unique Entity ID via SAM.gov, and project implementation must occur exclusively outside U.S. borders.
Centers For Disease Control-Ghc

POSTED

1 day ago

DEADLINE

in 29 days
View Details
NAICS: 541714
New
Grant
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)The National Cancer Institute is soliciting R33 grant applications to support the advanced development and rigorous validation of emerging technologies aimed at advancing cancer research and clinical care. This opportunity is intended for projects that have already addressed major feasibility barriers, as demonstrated by strong preliminary data, but require further refinement, optimization, and technical validation to achieve broad adoption within the scientific community. The focus is on technologies with new or substantially improved capabilities for measuring, analyzing, modeling, or interrogating cancer-related biological systems, including advanced molecular and cellular platforms, multi-omic and spatial profiling methods, next-generation imaging and sensing tools, immuno-engineering approaches, and innovations in biospecimen handling and quality assessment. Proposals must center on cancer-specific applications, and applications that merely apply established technologies to novel biological questions without technological innovation are not eligible. This funding opportunity is part of the NCI’s Innovative Molecular Analysis Technologies Program and explicitly prohibits clinical trials. The goal is to accelerate progress in areas such as cancer biology, early detection, diagnosis, treatment, control, and epidemiology by enabling technologies that offer transformative potential for the research community. Projects must demonstrate clear potential for widespread utility in cancer research while maintaining a tight focus on technical advancement rather than application-specific hypotheses. All applications must be submitted through the designated grants portal, and inquiries should be directed to the IMAT Program Contact provided. The opportunity was posted in July 2026 and is open to applicants seeking to bridge the gap between initial innovation and scalable adoption in cancer science.
National Institutes Of Health

POSTED

1 day ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Multiscale Reasoning For Human Physiology RFIThe Defense Advanced Research Projects Agency’s Biological Technologies Office is seeking input on cutting-edge technologies that enable multiscale reasoning across human physiology through this Request for Information, identified as DARPA-SN-26-100. The focus is on emerging tools including artificial intelligence systems, foundation models, computational frameworks, and datasets capable of integrating biological, physiological, and clinical data across multiple scales—from molecular and cellular levels to organ systems and whole-body responses. The goal is to advance the ability to model, predict, and interpret complex human physiological behavior using AI and data-driven approaches, with interest in non-traditional performers and innovative solutions from industry, academia, government labs, and healthcare organizations. Responses are due by August 10, 2026, and the solicitation falls under NAICS code 541714 for research and development in the physical, engineering, and life sciences. All submissions should be directed to Dr. Roozbeh Jafari, Program Manager at DARPA/BTO, via bioreasoning@darpa.mil. The office is located in Arlington, Virginia, and while no specific place of performance is defined, selected technologies may be developed and evaluated through future DARPA programs. This RFI does not constitute a solicitation for proposals or obligations but aims to inform upcoming funding opportunities in the field of physiological modeling and AI-driven biological insight.
Defense Advanced Research Projects Agcy

POSTED

2 days ago

DEADLINE

in 26 days
View Details
NAICS: 541714
New
Federal
Technical Support and Product Training for EMIT Assay SystemsThe contract provides for on-site or remote technical assistance, system calibration, and training services specifically tailored for laboratory personnel working with EMIT II Plus Assay systems and their associated reagents. This support is critical to ensure accurate operation, proper maintenance, and effective use of the analytical equipment, enabling consistent and reliable test results in laboratory settings. The scope encompasses hands-on training, troubleshooting guidance, and periodic calibration to meet performance standards, with services deliverable either at the client’s facility or through virtual means as needed. This subcontract is associated with the Department of Defense under the agency identifier FA3016 502 Cons Cl and is classified under NAICS code 541714, indicating scientific and technical consulting services. The place of performance is designated as DWG with a zip code of 78236, suggesting the primary operational location is in or near San Antonio, Texas. The solicitation was posted on July 10, 2026, with a response deadline of July 20, 2026, at 3:00 PM, requiring interested parties to submit proposals within this narrow window. The contract does not specify any set-aside status, and no point of contact information has been provided in the posting.
FA3016 502 Cons Cl

POSTED

5 days ago

DEADLINE

in 5 days
View Details